Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2V9RQ
|
|||
| Drug Name |
GDX012
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Company |
GammaDelta Therapeutics London, United Kingdom
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05001451) A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.